Surrozen, Inc. (NASDAQ:SRZN) Given Average Rating of “Moderate Buy” by Analysts

Shares of Surrozen, Inc. (NASDAQ:SRZN) have been given an average recommendation of “Moderate Buy” by the five brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $42.00.

A number of equities research analysts have weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a report on Tuesday, April 21st. TD Cowen assumed coverage on Surrozen in a report on Tuesday, April 21st. They issued a “buy” rating for the company. Wall Street Zen upgraded Surrozen from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $40.00 target price on shares of Surrozen in a report on Tuesday, March 24th. Finally, HC Wainwright reissued a “buy” rating and issued a $44.00 price objective (up from $36.00) on shares of Surrozen in a research note on Thursday, May 7th.

Surrozen Stock Performance

Shares of SRZN stock opened at $21.50 on Wednesday. The company has a market cap of $249.62 million, a P/E ratio of -0.57 and a beta of 0.51. The stock has a 50 day simple moving average of $28.24 and a two-hundred day simple moving average of $24.50. Surrozen has a fifty-two week low of $8.00 and a fifty-two week high of $35.00.

Surrozen (NASDAQ:SRZN) last issued its earnings results on Wednesday, May 6th. The company reported ($11.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($10.56). The business had revenue of $5.00 million during the quarter, compared to the consensus estimate of $4.00 million. Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 4,810.50%. On average, research analysts predict that Surrozen will post -7.2 earnings per share for the current year.

Insider Transactions at Surrozen

In other Surrozen news, COO Charles O. Williams sold 2,036 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $33.33, for a total value of $67,859.88. Following the completion of the sale, the chief operating officer owned 16,571 shares of the company’s stock, valued at approximately $552,311.43. This trade represents a 10.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Craig C. Parker sold 4,524 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $33.33, for a total value of $150,784.92. Following the completion of the sale, the chief executive officer directly owned 16,553 shares of the company’s stock, valued at $551,711.49. This trade represents a 21.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders bought 170,878 shares of company stock worth $4,232,976 and sold 8,144 shares worth $271,440. Company insiders own 31.74% of the company’s stock.

Institutional Investors Weigh In On Surrozen

A number of hedge funds have recently added to or reduced their stakes in SRZN. Geode Capital Management LLC grew its stake in Surrozen by 22.6% in the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after acquiring an additional 5,702 shares during the period. Armistice Capital LLC acquired a new stake in Surrozen in the second quarter valued at approximately $536,000. Vanguard Group Inc. grew its stake in Surrozen by 21.7% in the third quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock valued at $3,433,000 after acquiring an additional 47,468 shares during the period. Acuta Capital Partners LLC grew its stake in Surrozen by 5.0% in the third quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock valued at $2,299,000 after acquiring an additional 8,415 shares during the period. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in Surrozen in the third quarter valued at approximately $889,000. Institutional investors and hedge funds own 66.57% of the company’s stock.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.